HTA - Health Technology Assessment Report Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Year: 2023 Date: 2014 Author: Uluer AZ Source Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Study design (if review, criteria of inclusion for studies) HTA report Interventions Ivacaftor (Kalydeco) Related topics CFTR modulators therapy